Immuno-PET Imaging to Assess Target Engagement: Experience from (89)Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors by Menke-van der Houven Oordt, C.W. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/207391
 
 
 
Please be advised that this information was generated on 2020-09-10 and may be subject to
change.
F E A T U R E D A R T I C L E O F T H E M O N T H
Immuno-PET Imaging to Assess Target Engagement:
Experience from 89Zr-Anti-HER3 mAb (GSK2849330) in
Patients with Solid Tumors
C. Willemien Menke-van der Houven van Oordt*1, Adam McGeoch*2, Mats Bergstrom3, Iain McSherry4,
Deborah A. Smith5, Matthew Cleveland6, Wasfi Al-Azzam7, Liangfu Chen8, Henk Verheul1, Otto S. Hoekstra9,
Danielle J. Vugts9, Immanuel Freedman10, Marc Huisman9, Chris Matheny11, Guus van Dongen9, and
Sean Zhang12
1Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The
Netherlands; 2Division of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge,
Cambridge, United Kingdom; 3OMID Molecular Imaging Consultancy, Uppsala, Sweden; 4Clinical Pharmacology, Science,
and Study Operations, GlaxoSmithKline, Uxbridge, United Kingdom; 5Clin Pharm Advantage, LLC, Durham, North Carolina;
6Bioimaging, Platform Technology and Science, GlaxoSmithKline, Stevenage, United Kingdom; 7Biopharm Product Development
and Supply, GlaxoSmithKline, King of Prussia, Pennsylvania; 8Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King
of Prussia, Pennsylvania; 9Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam,
Amsterdam, The Netherlands; 10Freedman Patent, Harleysville, Pennsylvania; 11Oncology R&D, GlaxoSmithKline, King of Prussia,
Pennsylvania; and 12Hengrui Therapeutics, Inc., Princeton, New Jersey
See an invited perspective on this article on page 899.
PET imaging with radiolabeled drugs provides information on tumor
uptake and dose-dependent target interaction to support selection
of an optimal dose for future efficacy testing. In this immuno-PET
study of the anti–human epidermal growth factor receptor (HER3)
mAb GSK2849330, we investigated the biodistribution and tumor
uptake of 89Zr-labeled GSK2849330 and evaluated target engagement
as a function of antibody mass dose. Methods: 89Zr-GSK2849330
distribution was monitored in 6 patients with HER3-positive tumors
not amenable to standard treatment. Patients received 2 administrations
of 89Zr-GSK2849330. Imaging after tracer only was performed at base-
line; dose-dependent inhibition of 89Zr-GSK2849330 uptake in tumor
tissues was evaluated 2 wk later using increasing doses of unlabeled
GSK2849330 in combination with the tracer. Up to 3 PET scans (2
hours post infusion [p.i.] and days 2 and 5 p.i.) were performed after
tracer administration. Biodistribution and tumor targeting were
assessed visually and quantitatively using SUV. The 50% and 90%
inhibitory mass doses (ID50 and ID90) of target-mediated antibody
uptake were calculated using a Patlak transformation. Results: At
baseline, imaging with tracer showed good tumor uptake in all evalu-
able patients. Predosing with unlabeled mAb reduced the tumor up-
take rate in a dose-dependent manner. Saturation of 89Zr-mAb
uptake by tumors was seen at the highest dose (30 mg/kg). Despite
the limited number of patients, an exploratory ID50 of 2 mg/kg and
ID90 of 18 mg/kg have been determined. Conclusion: In this immuno-
PET study, dose-dependent inhibition of tumor uptake of 89Zr-
GSK2849330 by unlabeled mAb confirmed target engagement of
mAb to the HER3 receptor. This study further validates the use of
immuno-PET to directly visualize tissue drug disposition in patients
with a noninvasive approach and to measure target engagement at
the site of action, offering the potential for dose selection.
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The human epidermal growth factor receptor (HER) family of
receptor tyrosine kinases, also called ErbB, consists of 4 members:
HER1 (epidermal growth factor receptor [EGFR], or ErbB1), HER2
(ErbB2), HER3 (ErbB3), and HER4 (ErbB4) (1). These receptors
are important targets for rational drug design (1–3). Investigations
have traditionally focused on the first 2 HER family members
(EGFR and HER2), but growing evidence has also revealed a role
for HER3 in driving malignant growth (4–6). HER3 overexpression
has been shown to increase tumorigenesis in pancreatic adenocar-
cinoma (5) and is significantly associated with tumor progression
and poor prognosis in patients with gastric cancer (6). A metaanalysis
of HER3 expression and survival in solid tumors found that over half
of patients with melanoma, cervical cancer, and ovarian cancer
showed HER3 overexpression (7). Rates of overexpression in colo-
rectal, gastric, and breast cancer ranged from 20% to 60% (7).
HER3 somatic mutations have been identified in 11% of colon
and gastric cancers, including several hot-spot mutations, which pro-
mote oncogenic signaling in the presence of HER2 (8). These
findings suggest that HER3 can become an important therapeutic
drug target (9,10).
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GSK2849330 is a fully human monoclonal antibody (mAb) specific
to HER3 that has enhanced antibody-dependent cell-mediated cytotox-
icity and complement-dependent cytotoxicity mechanisms because of
its high binding affinity to human Fc-g-receptor RIIIa (respon-
sible for initiating antibody-dependent cell-mediated cytotoxicity)
and human complement protein C1q (responsible for initiating com-
plement-dependent cytotoxicity) (10,11). Preclinical investigations with
89Zr-labeled GSK2849330 PET imaging in human tumor-bearing mice
found dose-dependent, saturable uptake in HER3-positive CHL-1
tumors (12). A first-time-in-human phase 1 study (HER117158) re-
cently investigated the pharmacokinetic properties, safety, and tolera-
bility of GSK2849330 in participants with advanced HER3-positive
tumors (NCT01966445; not published at time of writing). However,
the optimal biologically active GSK2849330 dose has not been
identified, as mAbs do not generally induce significant toxicity
identifying a maximum tolerated dose.
Assuming that optimal therapeutic activity of mAbs requires
tumor accumulation and saturation of target receptor binding, an
understanding of the tumor-targeting capabilities of GSK2849330
and its interaction with the HER3 receptor would help identify an
optimal dose sufficient to fully saturate tumor HER3 receptors and
block HER3-mediated signaling. Immuno-PET with 89Zr-labeled
antibodies allows for in vivo, whole-body analyses of mAb biodistribu-
tion, tumor targeting, and accumulation (13). 89Zr has a half-life of 3.3 d,
allowing imaging over a period relevant to mAb biodistribution. By
repeated PET scanning, visual and quantitative assessment of (hetero-
geneous) antibody binding to its target receptor can be determined
over time throughout the body. This method has previously been
used to investigate potential patient selection for mAbs in clinical
use and to better understand novel mAbs used in phase 1 trials (14).
On target binding, internalization via endocytosis and sub-
sequent lysosomal antibody degradation causes 89Zr to be retained
within the cell. Thus, the recorded tissue signal on PET can be
related to the cumulative exposure of bound antibody over time
(area under the concentration–time curve [AUC]).
In practice, low doses of radiolabeled antibodies limit exposure
and side effects (15) while allowing for optimal tumor interaction
(16), therefore establishing a baseline for uptake. Coadministra-
tion of increasing doses of unlabeled mAb may prolong exposure
but results in competition for receptor binding leading to decreased
relative uptake of labeled mAb. The degree of target saturation can
be established by comparing tracer uptake to initial baseline scans.
The signal observed on PET imaging has 2 components: receptor-
mediated, specific uptake and nonspecific tissue residence due to the
presence of plasma and extracellular fluid in the tumor lesion. These
components can be separated by Patlak transformation, which
requires at least 2 imaging time points after tracer administration
(15). Thus, the dose dependency of receptor-mediated clearance at a
given site can be characterized by assessing the effect of different dose
levels of unlabeled antibody. A prediction of the antibody dose re-
quired to saturate the target at the site of interest can then be derived.
The aim of the present study was to characterize the biodis-
tribution and dose-receptor occupancy relationship of GSK2849330
labeled with 89Zr, in patients with advanced HER3-expressing solid
tumors. We hypothesized that baseline and on-treatment PET imag-
ing can predict the mass dose of therapeutic mAbs required for HER3
saturation on tumor lesions in patients.
MATERIALS AND METHODS
This was a phase 1, open-label, single-center PET imaging study of
the anti-HER3 mAb GSK2849330, labeled with 89Zr, in patients
with advanced solid tumors expressing HER3 (ClinicalTrials.gov
identifier NCT02345174; initiation, March 19, 2015; completion, June 2,
2016).
The study was approved by the appropriate regulatory and ethics
committee (Amsterdam UMC, location VUMC, Medisch Ethische Com-
missie), was conducted in accordance with the International Confer-
ence on Harmonisation for Good Clinical Practice and the principles
of the Declaration of Helsinki (17,18), and was monitored by an Internal
Safety Review Committee. All participants provided written informed
consent before study participation.
Preparation of 89Zr-GSK2849330
89Zr-NCS-Bz-DFO-GSK2849330 (89Zr-GSK2849330) was produced
as previously reported (12,19) and formulated to an infusion dose of
37 MBq (8 mg, 20 mL). The mean radiochemical purity assessed by
spin filter was 99.8% 6 0.1%. The mean radiochemical purity was
100%, and the mean protein integrity was 99.4% 6 0.5%, as determined
by size-exclusion high-performance liquid chromatography. The mean
immune reactive fraction, assessed by a binding assay using HER3-
coated plates, was 90.5% 6 4.1%. Sterility of each 89Zr-GSK2849330
batch was ensured by performing a medium fill immediately after final
filter sterilization of each batch. These procedures resulted in a sterile
final product with endotoxin levels of less than 0.3 EU/mL. For the
experimental work requiring additional mAb, antibody without 89Zr or
deferoxamine was used.
Patients
Enrolled patients were aged at least 18 years and had a histolog-
ically confirmed diagnosis of HER3-positive solid tumors not
amenable to standard treatment and an Eastern Cooperative Oncology
Group performance status of 0 or 1, with good organ function. HER3
positivity was defined as documented HER3 expression on the surface
of invasive tumor cells (archival tissue or fresh biopsy) determined by
staining intensity (11 [weak], 21 [moderate], or 31 [strong]) using an
analytically validated immunohistochemistry assay (Ventana Medical Sys-
tems, Inc.). The H-score method was used to quantify HER3 positivity on a
scale of 0–300 using the formula 1 · (percentage of weakly stained cells)1
2 · (percentage of moderately stained cells) 1 3 · (percentage of strongly
stained cells). Key exclusion criteria included leptomeningeal or brain
metastases, prior HER3-directed treatment, significant cardiovascular
risk, and evidence of another active malignancy. Anonymized individual
participant data and study documents can be requested for further re-
search from www.clinicalstudydatarequest.com.
Study Design
This 2-part imaging study was run in a staggered fashion with the
first-time-in-human study of GSK2849330. In part 1, all immuno-PET
imaging assessments were performed before treatment continuation
with unlabeled GSK2849330 in part 2 (Fig. 1). Study enrollment was
capped at 6 patients by the sponsor, after achievement of the primary
objective (characterization of in vivo biodistribution). In part 1, pa-
tients received a tracer-only dose of 37 MBq of 89Zr-GSK2849330
(8-mg or 24-mg mass dose mAb) by intravenous infusion on day
0 (dose 1). On day 14, a variable total 24–30 mg/kg dose of unlabeled
mAb was administered over 1 h by intravenous infusion, followed by a
second dose of 89Zr-mAb (dose 2) within 1 h after the end of the infusion
of unlabeled mAb.
The results of the first 2 patients were used to guide the baseline mass dose,
with the consideration that if the mass dose was too low, nonspecific, or
specific but non–tumor-related, binding would decrease systemic expo-
sure, leading to less drug–target binding at the tumor site (sink effect).
Response was evaluated according to Response Evaluation Criteria
in Solid Tumors, version 1.1, with the first analysis 12 wk after the
start of part 2 and subsequently every 8 wk.
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Objectives/Endpoints
The primary objective was to measure the in vivo biodistribution of
89Zr-GSK2849330 in patients with HER3-positive tumors. The sec-
ondary objectives were to establish the dose dependency of inhibition
of target-mediated uptake of 89Zr-GSK2849330 by unlabeled mAb,
further characterize GSK2849330 pharmacokinetics, measure the do-
simetry of 89Zr-GSK2849330, and assess safety, tolerability, and
immunogenicity.
The primary endpoints were quantitative parameters derived from
PET/CT images to assess uptake in tumor and normal tissues of
interest, reported with SUV for each volume of interest (VOI; SUVpeak
for tumor lesions and SUVmean for normal tissues and organs). Sec-
ondary endpoints included pharmacometric modeling of tumor uptake,
dosimetry, GSK2849330 pharmacokinetics, and safety.
PET Imaging
Whole-body PET low-dose CT and 89Zr-PET scans were acquired
on a European Association of Nuclear Medicine Research Ltd.–
accredited Gemini TF-64 or Ingenuity TF PET/CT scanner (Philips
Healthcare), as previously described (20). In the first 3 patients,
PET/CT scans were acquired at 2 h (for dosim-
etry purposes), 48 h (day 2), and 120 h (day 5)
after injection in the baseline study and at 48 h
(day 16) and 120 h (day 19) after injection after
the second tracer administration. In all remain-
ing patients, scans were acquired 48 and 120 h
after injection for each tracer administration
(Fig. 1). PET scans, including whole-body cov-
erage from brain to thighs, were acquired at
5 min per bed position.
Image Analysis
Tumor accumulation of 89Zr-GSK2849330
was assessed by a physician experienced in
PET image analysis and defined as visually
enhanced accumulation exceeding local back-
ground. In all 89Zr PET scans, tumor VOIs were manually delineated
and SUVpeak for lesions was derived using proprietary software (20).
Only tumor lesions measuring at least 2 cm were quantified, to avoid
partial-volume effects (20). The biodistribution of 89Zr-GSK2849330 to
liver, spleen, kidney, lung, bone marrow, and blood was quantified using
SUVmean. VOIs of liver, spleen, and kidney were manually delineated on
PET images using the low-dose CT as a reference. For lung, VOIs were
semiautomatically defined on the low-dose CT and projected on the PET
images. Fixed-size VOIs of 7.5 and 1.6 mL were placed in the lumbar
vertebrae to estimate bone marrow activity concentration and in the
aortic arch to estimate blood-pool activity concentration.
Plasma Concentration Analysis
Blood samples (plasma and serum) for 89Zr-GSK2849330 were
obtained before dosing and at 1, 3, 6, 12, and 24 h after injection
and immediately before PET scans. Plasma concentrations of 89Zr-
GSK2849330 were assessed by radioactivity measurements in a cross-
calibrated g-counter (Wallac Wizard 1480; PerkinElmer Inc.) and
expressed as SUV by normalization for infused activity and body
weight. Unlabeled plasma GSK2849330 was quantified using a
validated electrochemiluminescent immu-
noassay (21), with a concentration range of
50–5,000 ng/mL.
Modeling of Radioactivity
Uptake Data
A compartment model was used to repre-
sent tissue uptake of radioactivity (SUV; Fig.
2). In this model, 1 component of the tissue
signal reflects radiolabeled mAb in plasma
and interstitial space, which after a relevant
time is in equilibrium with plasma plus radio-
labeled mAb reversibly bound to the HER3
receptor or nontarget binding sites; after
equilibration, this component is proportional
to plasma radioactivity concentration. The
other component of the tissue signal reflects
irreversible internalization/residualization of
89Zr-mAb, which is dependent on receptor-
binding properties. Assuming that internaliza-
tion dominates over residence on the receptor,
we postulate that internalization rate is propor-
tional to the interstitial concentration; therefore,
after equilibration, cumulative internalization is
proportional to the AUC of the plasma radioac-
tivity concentration. Further assumptions of
the Patlak model have been previously de-
scribed (22,23).
FIGURE 1. Study overview. *2-h scan for first 3 patients.
FIGURE 2. Schematic illustration of compartment model for components of tissue radioactivity
and Patlak modeling. Cp(t) 5 radioactivity concentration; SUV 5 standardized uptake value.
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With these assumptions, the tissue signal SUV can be defined as a function
of plasma radioactivity concentration Cp(t) using the following equation:
SUV 5 ACpðtÞ1B
ðt
0
CpðtÞdt; Eq. 1
From a kinetic standpoint, the constant A is related to radiolabeled
mAb distribution in tissue, including plasma and a passive distribution in
interstitial tissues plus reversible binding to target receptor and nontarget
binding sites, whereas B is related to irreversible binding followed by
internalization after binding to HER3 receptors plus nonspecific internal-
izing binding, such as pinocytosis.
Equation 1 can be rearranged as:
SUV=CpðtÞ 5 A1B·AUCðtÞ=CpðtÞ; Eq. 2
which describes a straight line with slope 5 B and intercept 5 A.
This rearrangement of imaging data has been used previously in PET
imaging studies and is known as a Patlak plot (22,23). This study used
Patlak plots to determine the slope (B) values by linear fit of individual
PET data plotted at 2–3 time points.
Modeling of Dose-Dependent Target Engagement
Each tumor is expected to have a different level of HER3 expression.
Therefore, the derived parameters at different antibody mass doses were
normalized and expressed as percentages of baseline 8-mg values. The
B-value (slope) obtained after dosing of 89Zr-GSK2849330 in each pa-
tient was calculated as a percentage of the corresponding B-value from
the baseline study. These relative values, which showed the internaliza-
tion rates at increased mass doses compared with the baseline scan,
were plotted against mass doses and were fitted to a theoretic dose-
inhibition curve, with the 8-mg dose internalization rate set to 100%.
The formula used for the fit comprised a constant term, which is
thought to indicate nonspecific internalization, such as pinocytosis,
and a dose-dependent term:
RðdoseÞ 5 ½1 2 dose=ðdose1 ID50Þ·ð100 2 RnspÞ1Rnsp;
Eq. 3
where R is the ratio of ‘‘postdose B-value’’ to ‘‘predose B-value,’’
expressed as a percentage, and Rnsp is the expected percent ratio at
total inhibition of HER3 receptor internalization.
Equation 3 allows for evaluation of the 50% inhibitory mass dose
(ID50) of target-mediated uptake of 89Zr-mAb by unlabeled mAb.
Safety
Safety assessment included physical examinations, vital signs, 12-lead
electrocardiograms, echocardiograms, clinical laboratory tests, and moni-
toring for protocol-defined adverse events (AEs) and serious AEs.
The presence of anti-GSK2849330 antibodies was tested using a
validated electrochemiluminescent immunoassay (21). Organ and
whole-body radiation exposure were calculated using non–decay-
corrected organ and blood radioactivity concen-
trations using the OLINDA program (24).
Statistical Analysis
No formal hypotheses were tested for the
primary endpoint. Point estimates and corre-
sponding 95% confidence intervals by dose and
site were constructed for absolute changes or
percentage of changes from baseline in SUVpeak,
SUVmean, and volume of the region of interest.
RESULTS
Patients
Baseline characteristics for the 6 enrolled
patients, as well as mAb doses for imaging,
are summarized in Table 1. Drug plasma
TABLE 1
Patient Characteristics
Patient Primary tumor type mAb first/second administration H-score of membrane staining Best response*
1 Breast cancer 8 mg/24 mg 35 PD
2 Head and neck cancer 24 mg/1 mg/kg 80 ND
3 Cervical cancer 8 mg/30 mg/kg 184 PD
4 Ovarian cancer 8 mg/30 mg/kg 195 PD
5 Prostate cancer 8 mg/0.5 mg/kg 200 SD
6 Colorectal cancer 8 mg/—† 18 ND
*First response evaluation was performed at 12 wk after treatment initiation to allow sufficient time for beneficial treatment effect that
could be detected by RECIST 1.1.
†Patient 6 was discovered to have brain metastasis as seen in baseline immuno-PET study and therefore was removed from further
studies.
SD 5 stable disease; PD 5 progressive disease according to RECIST 1.1; ND 5 not determined.
FIGURE 3. Maximum-intensity projections of patient 1: prestudy 18F-FDG scan (A), 89Zr-GSK2849330
PET after 8 mg total mAb dose at 2, 48, and 120 h after infusion (B), 89Zr-GSK2849330 PET after
24 mg total mAb dose at 48 and 120 h after infusion (C).
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elimination and imaging in patients 1 and 2, who received total mAb
doses of 8 mg and 24 mg at baseline (day 0) and 24 mg and 1 mg/kg
on day 14, respectively, suggested that 8 mg of 89Zr-GSK2849330 was
an appropriate imaging dose (Figs. 3 and 4 and Supplemental Table
1A; supplemental materials are available at http://jnm.snmjournals.org).
At the 8-mg dose, circulating 89Zr-GSK2849330 remained in the
blood over time, as evidenced by radioactivity in the heart and major
blood vessels, with a constant and limited amount of tracer in the liver
independent of total mAb mass dose (known as the sink effect;
Supplemental Fig. 1 and data not shown). Note that plasma clearance
was discretely reduced with the added mass doses of unlabeled mAb.
Variable amounts of radioactivity were observed in the intestine, con-
sistent with biliary excretion of tracer. All subsequent patients re-
ceived a baseline mAb mass dose of 8 mg of 89Zr-GSK2849330
(Table 1). Subsequent total mass doses of 0.5 mg/kg (patient 5),
1 mg/kg (patient 2), and 30 mg/kg (patients 3 and 4) were admin-
istered on day 14. Patient 6 was discovered to have a brain metas-
tasis in the baseline immuno-PET study and was removed from
further studies. After completion of imaging procedures, patients
continued treatment with GSK2849330 at the current safe dose in
the first-time-in-human study.
89Zr-GSK2849330 PET Images
PET imaging showed a dominant vascular distribution of
radiolabeled mAb early after administration and a high uptake
of 89Zr-mAb in the liver and spleen. Later PET scans (48 and 120 h
after injection) indicated biliary excretion
but also retention in major organs (e.g.,
liver) (Figs. 3– 5 and Supplemental Figs. 1
and 2). Day 5 after injection was chosen
for quantification analysis of tumor uptake
because this time point showed the best tu-
mor-to-background contrast visually.
Tumor accumulation was visually observed
in all patients to different extents, with
SUVpeak ranging from 1.3 to 15.7 after
the first tracer administration and from
1.6 to 11.2 at the second administration
(Table 2).
Effect of Increased Mass Dose
The plasma radioactivity concentration
showed a relatively fast drug clearance, especially at the lowest
mass dose, with a slower clearance at higher doses (Supplemental
Table 1).
Reduced accumulation of radiolabeled mAb in tumor lesions
after treatment, defined by SUV, was observed in patients 3 and 4
(Fig. 6 and Supplemental Figs. 2 and 3). To further quantify dose
dependency, we performed a Patlak analysis to model irreversible
tumor accumulation and observed a marked reduction in radio-
tracer accumulation rate at the highest dose of 30 mg/kg, suggesting
saturation of the target, as seen in patients 3 and 4 (Supplemental
Fig. 4). The fitted curve is compatible with an ID50 of 2 mg/kg and
ID90 of 18 mg/kg of competing unlabeled mAb and a nonspecific
tumor accumulation of 30% (Fig. 7). Because of limited data, no
further statistical analyses were performed.
Pharmacokinetic Results (Nonradioactive)
Across doses of 8–30 mg/kg, the maximum GSK2849330 (nonradio-
active) plasma concentrations (Cmax) ranged from 2.1 to 1,515 mg/mL,
and AUC from time 0 to 48 h (AUClast) ranged from 41.1 to 79,804
h · mg/mL. Exposure (Cmax and AUClast) increased with increasing
doses and, in general, was dose-proportional (data not shown). Time
to Cmax was between 1.1 and 2.4 h (data not shown). Plasma radio-
activity pharmacokinetics, recalculated to mass concentration, and un-
labeled pharmacokinetics had a constant ratio of 0.96 0.19, suggesting
consistency of disposition processes between labeled and unlabeled
mAb (Supplemental Table 2 showing radioactivity and unlabeled phar-
macokinetic data).
Dosimetry
Radiation exposure was calculated for
the first 4 patients, and the effective whole-
body radiation dose was in the range of
17–22 mSv per 37 MBq, in line with pre-
vious studies (25) and predictions for the
present study. Supplemental Table 3 shows
a full listing of dosimetry data.
Safety, Immunogenicity,
and Response
The most-frequent AEs were decreased
appetite (grade 1; 2 patients receiving
30 mg/kg in part 1) and diarrhea (grade 1;
2 patients receiving 30 mg/kg in part 2).
One patient (patient 3) receiving 30 mg/kg
experienced a protocol-defined serious AE
of diarrhea during part 1, which was grade 3
FIGURE 4. Maximum-intensity projections of patient 2: prestudy CT scan showing multiple lung
lesions (A), 89Zr-GSK2849330 PET after 8 mg total mAb dose at 2, 48, and 120 h after infusion (B),
89Zr-GSK2849330 PET after 24 mg total mAb dose at 48 and 120 h after infusion (C).
FIGURE 5. Maximum-intensity projections of patient 5 with osseous metastases of prostate
cancer: SPECT scan after administration of 99mTc-hydroxydiphosphonate (A), PET scans showing
biodistribution and tumor accumulation of 89Zr-GSK2849330 at baseline with mass dose of 8 mg (day
5; after tracer injection only) (B) and on treatment with mass dose of 8 mg 1 0.5 mg/kg unlabeled
GSK2849330 (day 19, i.e., 5 d after tracer injection1 unlabeled mAb) (C). Arrows point to examples of
bone metastases; circles are over liver and rectum with 89Zr-GSK2849330-containing excretion.
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in intensity, was considered drug-related, and resolved within 4 d. One
patient (patient 2) receiving 30 mg/kg experienced a serious AE of
arrhythmia during part 2 of the study, which was grade 3 in intensity,
was considered drug-related, and resolved within 2 d. The patient was
withdrawn from the study. Of the 5 patients who received GSK2849330
and provided an immunogenicity blood sample, 3 (60%) developed
detectable levels of treatment-emergent anti-GSK2849330 antibodies.
The best response observed was stable disease at 12 wk in 1
patient (Table 1). There was no correlation between uptake measured
by PET imaging (SUV) and response to treatment with GSK2849330.
DISCUSSION
This study used immuno-PET imaging to track biodistribution
of 89Zr-GSK2849330, an anti-HER3 antibody under development
for treatment of HER3-positive tumors. 89Zr-mAb distribution was
as expected, with predominantly vascular distribution early after
tracer administration, accumulation in the liver, and significant tumor
uptake later. We observed a trend toward higher 89Zr-GSK2849330
accumulation with higher HER3 expression. The excellent visualiza-
tion of tumor lesions is likely, in part, a consequence of the PET
technique, with its superior resolution and sensitivity compared with
other nuclear modalities. Furthermore, the distinct HER3 tumor ex-
pression plus internalization and residualization of the radionuclide
contributes to high contrast between lesions and most normal organs.
Importantly, this study describes the dose-dependent inhibition of
tumor uptake of 89Zr-mAb by unlabeled mAb confirming target en-
gagement, that is, specific binding and internalization of anti-HER3
antibody by HER3 receptors in tumor tissues. It is important to
TABLE 2
SUVpeak for All Lesions and Time Points After First and Second mAb Administrations
First mAb administration Second mAb administration
Parameter First time point Second time point Third time point First time point Second time point
Patient 1
Hours after injection 2 48 119 49 117
SUVpeak
Bone lesion BLQ 2.49 3.12 2.30 2.90
Bone lesion 4.19 4.55 2.60 4.80 3.51
Soft-tissue lesion 6.47 5.42 3.14 4.59 3.53
Soft-tissue lesion 2.26 4.53 3.60 4.87 3.10
Bone lesion 4.32 5.64 3.88 6.90 5.95
Bone lesion 3.36 3.23 2.89 3.36 2.96
Patient 2
Hours after injection 2 46 115 44 118
SUVpeak, lung lesion 2.22 1.87 1.57 1.71 1.57
Patient 3
Hours after injection 2 50 116 49 139
SUVpeak
Lung lesion BLQ 2.19 1.26 3.59 3.78
Bone lesion BLQ 3.92 4.83 2.85 3.13
Bone lesion BLQ 5.30 5.87 5.78 6.20
Bone lesion BLQ 5.45 6.12 5.49 4.87
Patient 4
Hours after injection 2 51 116 45 115
SUVpeak, soft-tissue lesion NA 9.94 12.01 5.72 5.92
Patient 5
Hours after injection 2 42 138 40 113
SUVpeak
Lymph node lesion NA 3.69 3.84 3.11 3.97
Bone lesion 15.66 15.26 6.58 11.23
Lymph node lesion 4.45 4.34 3.32 3.95
Lymph node lesion 3.96 4.06 2.72 2.92
Lymph node lesion 3.22 2.64 4.22 3.41
Lymph node lesion 4.60 5.38 4.50 5.71
BLQ 5 below limit of quantification; NA 5 not applicable.
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consider what is meant by inhibition of accumulation rate and sat-
uration. The analyses reveal the degree to which a small additional
amount of mAb in plasma could bind to the HER3 receptor and be
internalized if there was no target-mediated drug disposition (TMDD).
Hence, it is a factor related to receptor functionality and not the
amount of mAb that under TMDD conditions can access the tumors.
This could be a relevant approximation of how the receptor system is
saturated with respect to handling a constant level of heregulin. The
SUVs by themselves represent capture of radioactivity by both spe-
cific and nonspecific phenomena, whereas Patlak analysis attempts to
separate out the specific binding and internalization processes. These
findings corroborate preclinical data reporting a dose-dependent, sat-
urable uptake of 89Zr-GSK2849330 in HER3-positive (CHL-1) hu-
man xenograft tumors (12).
Compared with immunohistochemistry, showing HER3 expres-
sion in a biopsy at a single time point, immuno-PET imaging visualizes
HER3 mAb binding and internalization of the whole body and
over time. Thus, immuno-PET allows in vivo investigation of mAb
pharmacokinetics, such as dose-dependent inhibition of tumor
uptake. Indeed, with the highest mass dose of 30 mg/kg, we
observed reduced uptake of 89Zr-GSK2849330 as measured by
SUVpeak in tumor lesions (patients 4 and 5). In patient 1, no changes
were observed, as expected with a similar mass dose (8 vs. 24 mg).
Using the Patlak approach, we see saturation of irreversible HER3
accumulation with increasing mass dose in
patients 3 and 4. Patient 2 did not show sat-
uration of reversible or irreversible HER3
binding, possibly because of the relatively
low HER3 expression (the relatively low
SUVpeak is consistent with this hypothesis).
Additionally, interpatient and intralesion het-
erogeneity in uptake of radiolabeled anti-
bodies, as described previously (26), can
lead to the observed heterogeneity in tracer
uptake. Overall, our results are compatible
with the saturation of HER3 by increasing
unlabeled mAb supporting target engage-
ment of GSK2849330 to HER3 receptors
in the tumor tissues, with an estimated ID50
of 2 mg/kg. This fits well with the preclini-
cally determined ID50 of 0.5 mg/kg (data
not shown). Target saturation is expected
to be achieved at ID90 and is estimated
to be approximately 18 mg/kg based on the current Patlak model,
which is considerably lower than the dose identified with the
maximum-tolerated-dose approach (i.e., 30 mg/kg). However,
because of the limited number of patients, these values are only
an estimation and no statistical analysis can be performed.
A recent study with 89Zr-lumretuzumab, another anti-HER3 mAb,
failed to show saturation of HER3 binding with increasing mass doses
of mAb, despite using maximum doses similar to those in this study
(27). Possibly, the binding epitope of the 2 mAbs differs, resulting in
different levels of internalization and degradation of the HER3 re-
ceptor. However, they showed a near-complete downregulation of
HER3 in serial skin biopsies, suggesting that saturating doses of
HER3 binding could be achieved with lumretuzumab. Alternatively,
our approach of serially imaging the same patient may be more
informative in cases of variable tumor tracer accumulation between
patients (as in this study), as baseline binding characteristics can be
compared with those on treatment. Potentially, HER3 downregula-
tion due to first tracer administration could interfere with imaging on
treatment. However, although no on-treatment (skin) biopsies were
available for immunohistochemistry of the HER3 receptor, baseline
mAb mass dose was extremely low, making such an effect unlikely.
89Zr-GSK2849330 biodistribution showed significant uptake of 89Zr-
mAb in the liver and spleen. This finding is likely due to both increased
blood flow and Fc fragment of immunoglobulin G receptor IIIa binding
(28). In addition, high tracer accumulation in normal liver tissue may
also be due to catabolism, as 16% of immunoglobulin G is eliminated
via the liver and subsequently excreted (29). This is in the same range
as the average percentage injected dose found in the liver, that is, 20%
(data not shown). Similar findings were observed in the lumretuzumab
study, which reported the highest uptake of 89Zr-lumretuzumab in the
liver and intestine (27). A methodologic aspect that strengthens con-
fidence in this study is the good agreement between the plasma
pharmacokinetics of the antibody and the equivalent concentration
calculated through the SUVs in plasma (Supplemental Table 2).
Clinical trials in other tumor types have shown the potential of
89Zr-immuno-PET as a means of directly visualizing mAb target
engagement (14,27,30). This present study is, to our knowledge,
the first immuno-PET study describing target saturation in vivo in hu-
mans using an intricate design involving multiple tracer administrations
and imaging time points. Despite the small patient cohort, this study
demonstrates the feasibility of such an approach and provides dosing
guidance for further evaluation of mAbs.
FIGURE 6. Images of patient 4: prestudy axial CT scan (A), 89Zr-GSK2849330 PET/CT after
8-mg total mAb dose at 120 h after injection (B), 89Zr-GSK2849330 PET/CT after 30 mg/kg total
mAb dose at 120 h after injection (C). Circles highlight large metastasis in pelvic region. Both
89Zr-GSK2849330 PET images are normalized to same intensity.
FIGURE 7. Modeling of tumor engagement with data from all patients.
Gray circles indicate baseline studies normalized to 100%. Dotted line
indicates expected nonspecific internalization, such as pinocytosis.
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Patlak modeling was applied to determine the amount of drug
internalized, taking into consideration the dose dependence of the
plasma radioactivity pharmacokinetics (TMDD). This approach
has the advantage of both normalizing the observed TMDD and
providing relevant information with a limited number of scans.
However, verification of the model assumptions was made difficult
by logistical issues, such as appropriate selection of time points to
ensure analysis of the linear part of the Patlak graph. Significant
variability is eliminated by serial imaging of the same patients with
different mAb doses, allowing for enrollment of fewer patients. We
acknowledge that, because of its limited sample size, this study
provides a demonstration of the conceptual design and feasibility of
our approach rather than a robust statistical outcome. Patients
imaged with intermediate mass doses between 0.5 and 30 mg/kg
would have established more precise estimates of ID50 and ID90.
CONCLUSION
This immuno-PET study explored the biodistribution and dose-
dependent tumor uptake of 89Zr-GSK2849330 in patients with
advanced solid tumors expressing HER3. Modeling of the uptake
kinetics of 89Zr-GSK2849330 in tumors revealed a dose-depen-
dent inhibition of rate of accumulation, indicating saturation of
HER3 receptor at the highest mAb doses. This demonstrates the
potential for immuno-PET to directly visualize tissue drug dispo-
sition in patients and to noninvasively measure target engagement
at the site of action, offering the potential for dose selection.
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